Featured Research

from universities, journals, and other organizations

Allergy tablet approval warrants caution for some

Date:
April 2, 2014
Source:
American College of Allergy, Asthma and Immunology (ACAAI)
Summary:
A pill a day keeps spring allergies away. In a perfect world, it would be that easy. And for those suffering from an allergy to some grasses, the Food and Drug Administration‘s (FDA) approval of the oral dissolvable tablets designed to help treat symptoms may be beneficial. But for the majority of seasonal sufferers allergic to pollens from the more than 30 other pollinating species, relief isn’t that easy.

A pill a day keeps spring allergies away. In a perfect world, it would be that easy. And for those suffering from an allergy to some grasses, the Food and Drug Administration's (FDA) approval of the oral dissolvable tablets designed to help treat symptoms may be beneficial. But for the majority of seasonal sufferers allergic to pollens from the more than 30 other pollinating species, relief isn't that easy.

Related Articles


"The approval of oral immunotherapy tablets is advancement in the right direction," said allergist Michael Foggs, MD, president of the American College of Allergy, Asthma and Immunology (ACAAI). "It's an additional treatment option for those who are allergic to some types of grasses, but not those allergic to other varieties of grass, trees and weeds."

According to ACAAI, those with seasonal allergies can be affected by the pollen of 11 different types of weeds and trees, and eight varieties of grass. Mold is also problematic in the spring, summer and fall months.

Fortunately, there is a long-standing solution for those suffering from multiple allergies. Immunotherapy, also known as allergy shots, has been used for 100 years and is a natural treatment. Each injection can be customized to an individual's allergic needs. Allergy shots can modify and prevent allergy progression while also relieving symptoms. They are also fast acting and cost-efficient.

"It would be ideal if tablets could be customized like allergy shots, but that's not on the horizon yet," said Dr. Foggs. "Since allergy treatment is not a one-size-fits-all approach, treatment needs to be tailored to an individual's needs."

Although the approved tablets are beneficial only for those suffering from some forms of grass allergy, the FDA's approval will help open the door for others getting approved, such as tablets for ragweed and dust mite allergy.

The best way to conquer allergy symptoms is to avoid allergens, according to the ACAAI. During the spring sneezing season, sufferers should: • Limit time outdoors when pollen counts are highest (midday and afternoon hours) • Keep windows in the car and home closed • Wash hair after working or exercising outdoors

Allergy sufferers should talk with their board-certified allergist to learn which treatment is best suited for their needs.


Story Source:

The above story is based on materials provided by American College of Allergy, Asthma and Immunology (ACAAI). Note: Materials may be edited for content and length.


Cite This Page:

American College of Allergy, Asthma and Immunology (ACAAI). "Allergy tablet approval warrants caution for some." ScienceDaily. ScienceDaily, 2 April 2014. <www.sciencedaily.com/releases/2014/04/140402105559.htm>.
American College of Allergy, Asthma and Immunology (ACAAI). (2014, April 2). Allergy tablet approval warrants caution for some. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2014/04/140402105559.htm
American College of Allergy, Asthma and Immunology (ACAAI). "Allergy tablet approval warrants caution for some." ScienceDaily. www.sciencedaily.com/releases/2014/04/140402105559.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins